


AMENDMENTS TO THE CLAIMS

1. **(Currently Amended)** A compound of the formula Y:



where;

$R_1$  is O, S;

$R_2$  is pyrid-2-yl, substituted at the 5 position with the  $-(CHR_{11})_p-E-(CHR_{11})_q-R_{10}$  moiety a nitrogen-containing heterocycle, wherein a nitrogen is located at the 2 position relative to the (thio)urea bond;

$R_3$  is  $H$ ,  $C_1-C_3$ -alkyl;

$R_4$ - $R_7$ ,  $R_4$  and  $R_7$  are fluoroindependently selected from  $H$ ,  $C_1-C_6$ -alkyl,  $C_2-C_6$ -alkenyl,  $C_2-C_6$ -alkynyl, halo $C_1-C_6$ -alkyl,  $C_4-C_6$ -alkanoyl, halo $C_4-C_6$ -alkanoyl,  $C_4-C_6$ -alkoxy, halo $C_4-C_6$ -alkoxy,  $C_4-C_6$ -alkyloxy- $C_4-C_6$ -alkyl, halo $C_4-C_6$ -alkyloxy- $C_4-C_6$ -alkyl, hydroxy $C_4-C_6$ -alkyl, amino $C_4-C_6$ -alkyl, carboxy $C_4-C_6$ -alkyl, cyano $C_4-C_6$ -alkyl, amino, carboxy, carbamoyl, cyano, halo, hydroxy, keto;

$R_5$  and  $R_6$  are  $H$ ;

X is  $-(CR_8R_8')_n-D-(CR_8R_8')_m$ ;

D is a bond,  $-NR_9$ ,  $-O$ ,  $-S$ ,  $S(=O)$  or  $S(=O)_2$ ;

m is 1

~~n and m are independently 0, 1 or 2, provided that they are not both 0 when D is a bond;~~

~~R<sub>8</sub> and R<sub>8</sub>' are independently H, C<sub>1</sub>-C<sub>3</sub>-alkyl, haloC<sub>1</sub>-C<sub>3</sub>alkyl, hydroxy, or R<sub>8</sub> and R<sub>8</sub>' together with their adjacent C atom is -C(=O)-;~~

~~R<sub>9</sub> is independently H, C<sub>1</sub>-C<sub>3</sub>-alkyl;~~

~~E is -CH<sub>2</sub>-, -CHOH-, -C(=O)-, -NR<sub>9</sub>-, -O-, -S-, -S(=O)<sub>2</sub>-;~~

~~p and q are independently 0, 1 or 2, where p+q ≤ 2;~~


~~R<sub>10</sub> is pyrid-3-yl, optionally substituted with halo or cyanoan optionally substituted, saturated or unsaturated 5-7 membered carbocyclic ring or an optionally substituted, saturated or unsaturated 5-7 membered heterocyclic ring containing 1 to 3 hetero atoms selected from O, N and S;~~

~~R<sub>11</sub> is independently H, C<sub>1</sub>-C<sub>3</sub>-alkyl, haloC<sub>1</sub>-C<sub>3</sub>alkyl, hydroxy~~

~~with the proviso that -(CHR<sub>11</sub>)<sub>p</sub>-E-(CHR<sub>11</sub>)<sub>q</sub>-R<sub>10</sub> is not unsubstituted phenoxy;~~

~~and pharmaceutically acceptable salts and prodrugs thereof.~~

2. **(Original)** A compound according to claim 1, wherein R<sub>1</sub> is O.
3. **Canceled**
4. **Canceled**
5. **Canceled**
6. **(Original)** A compound according to claim 1, wherein the cyclopropyl moiety has an enantiomeric excess of the conformation depicted in the partial formulae:



where X is as defined, Y is the bridge to the (substituted) phenyl ring depicted in formula I and Z is bond to the urea- $R_2-(CHR_{11})_p-E-(CHR_{11})_q-R_{10}$  moiety depicted in formula I.

7. **(Original)** A compound according to claim 1 wherein the compound of formula I comprises an enantiomeric excess of the isomer showing negative optical activity.

8. – 26. **Canceled**

27. **(Currently Amended)** A compound according to claim 126, wherein  $R_{10}$  is cyano or fluoro substituted pyrid-3-yl or ~~pyrid-4-yl~~.

28. **(Currently Amended)** A pharmaceutical composition comprising a compound as defined in any ~~preceding one of~~ claims 1, 6, 7, 9 and 27, and a pharmaceutically acceptable vehicle or diluent therefor.


29. **(Currently Amended)** A composition according to claim 28, further comprising 1 to 3 additional HIV antivirals selected from the group consisting of AZT, ddI, ddC, D4T, 3TC, DAPD, alovudine, abacavir, adefovir, adefovir dipivoxil, bis-POC-PMPA, foscarnet, efavirenz, trovirdine, capravirine, nevirapine, delaviridine, tipranavir, emtricitabine, omaciclovir, valomaciclovir stearate, TMC-126, TMC-125, TMC-120, efavirenz, loviride, ritonavir, kaletra, lopinavir, saquinavir, lasinavir, indinavir, amprenavir, amprenavir phosphate and nelfinavir.

30. **(Currently Amended)** A method of treatment or prophylaxis of HIV-1 infections comprising administering to a patient infected with HIV-1 an effective amount of the compound as defined by claim 1.

31. **(Previously Presented)** The method of claim 30, wherein said HIV-1 infection is a drug escape mutant.


32. **(Previously Presented)** The method of claim 31, wherein said drug escape mutant comprises the K103I mutation.

33. **(NEW)** The method of claim 30, wherein the compound has the formula:



34. **(NEW)** A compound according to claim 27, wherein R<sub>10</sub> is 6-cyano-pyrid-3-yl.

35. **(NEW)** The compound of claim 1 with the formula:



36. **(NEW)** A pharmaceutical composition comprising the compound of claim 34 and a pharmaceutically acceptable vehicle or diluent therefor.

37. **(NEW)** The pharmaceutical composition of claim 35, further comprising 1-3 additional antivirals selected from the group consisting of AZT, ddI, ddC, D4T, 3TC, DAPD, alovudine, abacavir, adefovir, adefovir dipivoxil, bis-POC-PMPA, foscarnet, efavirenz, trovirdine, capravirine, nevirapine, delaviridine, tipranavir, emtricitabine, omaciclovir, valomaciclovir stearate, TMC-126, TMC-125, TMC-120, efavirenz, loviride, ritonavir, kaletra, lopinavir, saquinavir, lasinavir, indinavir, amprenavir, amprenavir phosphate, and nelfinavir.